HARROW, INC. — Director's Dealing 2015

May 20, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Imprimis Pharmaceuticals, Inc. (IMMY)
CIK: 0001360214
Period of Report: 2015-05-18

Reporting Person: Opaleye Management Inc. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Imprimis Pharmaceuticals, Inc.	1167199	Indirect

Footnotes

F1: Securities reported herein for Opaleye Management, Inc. (the "Company) represent Common Stock beneficially owned and held of record by the Company and Opaleye, L.P., a private fund for which the Company serves as the investment manager (the "Fund"). James Silverman is the President and sole shareholder of the Company. The Company, the Fund and Mr. Silverman (the "Reporting Persons") are each beneficial owners and have an address of 9B Russell Street, Cambridge, MA 02140. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares and warrants in which the Reporting Persons have no actual pecuniary interest therein.